Hexagon

INSPIRATION

Most people globally, pass away from counterfeit/substandard drugs relying on proper pharmaceutical medications to manage chronic illness, prevent pregnancy, and treat life threatening diseases. Yet, with all precautions put up, these counterfeits still find their way into the market to put lives at stake.

WHAT IT DOES

Hexagon is being built to help stop the number of falsified and substandard pharmaceutical drugs produced that put lives at stake. Hexagon is basically a verification system to allow users to check the authentication of a drug, its use, effects, and also report these counterfeits.

HOW WE ENVISION BUILDING HEXAGON ON THE EOS NETWORK / ANTELOPE BLOCKCHAIN

Frontend: The front-end will be assembled utilizing reactjs for best user experience and interactivity, and furthermore exploit the various existing parts in the environment. Interactivity: To interact with the network, we will use eosjs, due to its simplicity and ease of use. Finally, the smart contract will be written in EOS smart contract language, C++, with the following features:

Allow manufacturers of drugs register their drugs on the smart contract.
A function for drug owners to generate new unique codes for their drugs (which then saves the hashed string without saving the original unique code).
A public function which can be used to verify that a code is valid (i.e., verify authenticity of a drug).

HOW HEXAGON WOULD WORK

FOR USERS

Users will only need to scan or input the unique code of the drug on hexagon to check for a drug’s authenticity.
To check a drug’s usage, effect, and every other information. Users will need to input the generic name of the drug on hexagon.
When a drug is checked and it is falsified, a user can report that drug alongside information of where it was bought from. FOR MANUFACTURERS
A registered manufacturer will have a dashboard where they can generate new codes to use for their drugs.
On the manufacturer’s dashboard, they would be able to update information about a drug directly by themselves.
These registered manufacturers will also gain access to see reported drugs, alongside information about the drug and where it was bought.